share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K：重大事件
美股sec公告 ·  07/24 07:49
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc. announced on July 24, 2024, that it has regained compliance with the Nasdaq minimum bid price requirement. The company's common stock had maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from July 8 to July 19, 2024. This achievement has led to the closure of the listing matter, as confirmed by the Nasdaq Listing Qualifications Department. Virpax specializes in developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral indications. The company is working on FDA approval for two prescription drug candidates and has cooperative research and development agreements with the NIH and DOD. Additionally, Virpax is pursuing approval for two nonprescription products, including one for inhibiting viral replication in influenza or SARS-CoV-2.
Virpax Pharmaceuticals, Inc. announced on July 24, 2024, that it has regained compliance with the Nasdaq minimum bid price requirement. The company's common stock had maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from July 8 to July 19, 2024. This achievement has led to the closure of the listing matter, as confirmed by the Nasdaq Listing Qualifications Department. Virpax specializes in developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral indications. The company is working on FDA approval for two prescription drug candidates and has cooperative research and development agreements with the NIH and DOD. Additionally, Virpax is pursuing approval for two nonprescription products, including one for inhibiting viral replication in influenza or SARS-CoV-2.
Virpax药品公司于2024年7月24日宣布已恢复符合纳斯达克最低买盘价格要求。该公司的普通股已连续10个business days维持了1.00美元或更高的收盘买盘价格，从2024年7月8日至7月19日。该成就已导致该事项的结案，由纳斯达克上市资格部门确认。Virpax专门开发无成瘾性的药品，用于疼痛管理、创伤后应激障碍、中枢神经系统障碍和抗病毒指示。该公司正在申请FDA批准两种处方药品候选者，并与 NIH 和 DOD 签订了合作研究和开发协议。此外，Virpax正在寻求批准两种非处方产品，其中一种用于抑制流感或SARS-CoV-2的病毒复制。
Virpax药品公司于2024年7月24日宣布已恢复符合纳斯达克最低买盘价格要求。该公司的普通股已连续10个business days维持了1.00美元或更高的收盘买盘价格，从2024年7月8日至7月19日。该成就已导致该事项的结案，由纳斯达克上市资格部门确认。Virpax专门开发无成瘾性的药品，用于疼痛管理、创伤后应激障碍、中枢神经系统障碍和抗病毒指示。该公司正在申请FDA批准两种处方药品候选者，并与 NIH 和 DOD 签订了合作研究和开发协议。此外，Virpax正在寻求批准两种非处方产品，其中一种用于抑制流感或SARS-CoV-2的病毒复制。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息